Citigroup Upgrades Qiagen (NYSE:QGEN) to Hold

Qiagen (NYSE:QGEN) was upgraded by stock analysts at Citigroup to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

Other equities analysts have also issued research reports about the company. TD Cowen reissued a “hold” rating on shares of Qiagen in a research note on Wednesday, July 15th. JPMorgan Chase & Co. restated a “neutral” rating and set a $52.00 target price (down from $55.00) on shares of Qiagen in a research report on Thursday, October 22nd. UBS Group initiated coverage on Qiagen in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 price target for the company. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Tuesday, July 14th. Finally, Barclays set a $40.00 price objective on shares of Qiagen and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and a consensus target price of $45.01.

Qiagen Price Performance

Shares of QGEN stock opened at $50.36 on Monday. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The stock has a market cap of $10.38 billion, a PE ratio of 25.81, a PEG ratio of 5.01 and a beta of 0.61. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The firm’s 50 day moving average price is $44.58 and its two-hundred day moving average price is $42.70.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, analysts forecast that Qiagen will post 2.44 EPS for the current year.

Institutional Trading of Qiagen

Several hedge funds have recently added to or reduced their stakes in QGEN. Hilltop National Bank acquired a new stake in Qiagen during the 2nd quarter worth $50,000. Integrated Wealth Concepts LLC acquired a new position in Qiagen in the second quarter valued at about $59,000. Allworth Financial LP grew its stake in Qiagen by 20.8% in the second quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after acquiring an additional 317 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Qiagen by 46.8% in the first quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock worth $110,000 after acquiring an additional 876 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Qiagen by 70.4% in the second quarter. GAMMA Investing LLC now owns 3,521 shares of the company’s stock worth $138,000 after acquiring an additional 1,455 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.